We are live on ! Find out more
EDIT icon

Editas Medicine
EDIT

84 hedge funds and large institutions have $381M invested in Editas Medicine in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

290% more call options, than puts

Call options by funds: $335K | Put options by funds: $86K

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

64.09% more ownership

Funds ownership: 0% → 64.09% (+64%)

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

27% more capital invested

Capital invested by funds: $300M → $381M (+$81M)

12% more funds holding

Funds holding: 75 → 84 (+9)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
84
Holders Change
+9
Holders Change %
+12%
% of All Funds
2.1%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
20
Increased
23
Reduced
18
Closed
10
Calls
$335K
Puts
$86K
Net Calls
+$249K
Net Calls Change
+$325K

Top Buyers

1
EC
EcoR1 Capital
California
+$9.51M
2
BFA
BlackRock Fund Advisors
California
+$8.13M
3
FCMI
Foresite Capital Management III
California
+$4.17M
4
CS
Credit Suisse
Switzerland
+$2.14M
5
Norges Bank
Norges Bank
Norway
+$1.38M

Top Sellers

1
PVMCV
Polaris Venture Management Co VI
Massachusetts
-$5.45M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.69M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.73M
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$1.17M
5
Deutsche Bank
Deutsche Bank
Germany
-$847K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
$9K – – –
MFW
77
Mosaic Family Wealth
Missouri
$9K +$8.5K +560 New
IP
78
Intellectus Partners
California
$8K +$7.59K +500 New
MAM
79
Meeder Asset Management
Ohio
$7K +$6.95K +458 New
TCM
80
Tradewinds Capital Management
Washington
$4K -$5.71K -376 -58%
BlackRock
81
BlackRock
New York
$4K – – –
CHP
82
Cable Hill Partners
Oregon
$3K – – –
ECM
83
Elgethun Capital Management
South Dakota
$3K +$3.04K +200 New
SPIA
84
Steward Partners Investment Advisory
New York
$3K +$3.04K +200 New
Renaissance Technologies
85
Renaissance Technologies
New York
– -$1.73M -128,400 Closed
Arrowstreet Capital
86
Arrowstreet Capital
Massachusetts
– -$1.17M -86,598 Closed
SOMRS
87
State of Michigan Retirement System
Michigan
– -$709K -52,573 Closed
SSA
88
Schonfeld Strategic Advisors
New York
– -$189K -13,982 Closed
AAM
89
Aberdeen Asset Management
United Kingdom
– -$182K -13,491 Closed
EMG
90
Ellington Management Group
Connecticut
– -$145K -10,757 Closed
JP Morgan Chase
91
JP Morgan Chase
New York
– -$24K -1,812 Closed
AIM
92
Acrospire Investment Management
Illinois
– -$8K -600 Closed
SO
93
STRS Ohio
Ohio
– -$8K -600 Closed
AG
94
Advisor Group
Arizona
– -$3K -200 Closed
1 2 3
4

EDIT Hedge Fund Activity: Q4 2016 in Review

84 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2016, worth a combined $381M — up 27% from $300M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EDIT positions and 10 closed out — a net gain of 10 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.51M. The largest seller was Polaris Venture Management Co VI, cutting an estimated $5.45M.

  • 84 institutional investors held Editas Medicine (EDIT) as of Q4 2016, up from 75 in Q3 2016.
  • Funds reported $381M of Editas Medicine stock for Q4 2016, up 27% quarter-over-quarter.
  • 20 funds opened new Editas Medicine positions in Q4 2016 and 10 closed out, a net change of +10 holders.
  • The largest Editas Medicine buyer in Q4 2016 was EcoR1 Capital, an estimated $9.51M added.
  • The largest Editas Medicine seller in Q4 2016 was Polaris Venture Management Co VI, an estimated $5.45M sold.

Based on aggregated 13F filings for Q4 2016.